Metformin Dosage Guide: Starting Doses, Titration Steps and Maximum Daily Limits

Metformin is the most prescribed oral medicine for type 2 diabetes in the world, and the most common reason people abandon it is a dose that was started too high or increased too quickly. The approved US prescribing information is unusually direct about this. It states that there is no fixed dosage regimen for metformin, that the dose must be individualised on effectiveness and tolerance, and that treatment should begin at a low dose with gradual escalation, both to reduce gastrointestinal side effects and to identify the smallest dose that still controls blood glucose.

This guide sets out the actual numbers from the label: starting doses, increment sizes, how long to wait between increases, and the ceilings for immediate-release and extended-release tablets. It also covers the kidney function thresholds that decide whether metformin can be prescribed at all, which most dosing summaries leave out even though it is the step that most often changes the answer.

Maximum daily doses at a glance

Three numbers do most of the work. Everything else is titration towards one of them.

Formulation	Population	Maximum recommended daily dose	How it is taken
Immediate-release tablets	Adults	2,550 mg per day	Divided doses with meals
Immediate-release tablets	Children 10 to 16 years	2,000 mg per day	Divided doses with meals
Extended-release tablets	Adults	2,000 mg per day	Once daily with the evening meal

Note the gap between the two adult ceilings. Extended-release metformin stops at 2,000 mg per day. Immediate-release goes to 2,550 mg. Anyone who genuinely needs more than 2,000 mg has to be on the immediate-release form, which is one of the more practical reasons the older tablets are still widely used.

Immediate-release titration schedule

The label gives two acceptable starting points and two matching escalation paths:

• Start at 500 mg twice daily with meals. Increase by 500 mg per week until 2,000 mg per day in divided doses.
• Start at 850 mg once daily with a meal. Increase by 850 mg every two weeks until 2,000 mg per day in divided doses.
• A third documented route: move from 500 mg twice daily to 850 mg twice daily after two weeks.
• If more glucose lowering is still needed, the dose can go up to 2,550 mg per day. Above 2,000 mg per day, splitting into three doses with meals is often better tolerated than two.

Two details matter more than the arithmetic. The first is that every dose is taken with food, not before or between meals. The second is that the weekly interval is not a formality. It exists because gastrointestinal symptoms cluster in the days after each increase, and stepping up before the previous step has settled makes the whole course harder to complete.

Available immediate-release strengths on this site include Glycomet 250mg, Glycomet 500mg, Glycomet 850mg, Glycomet 1000mg and Okamet 500 from Cipla. The 250 mg tablet is genuinely useful for people who could not tolerate 500 mg twice daily and need a slower on-ramp.

Extended-release titration schedule

Extended-release metformin follows a simpler path because it is a once-daily product:

• Start at 500 mg once daily with the evening meal.
• Increase by 500 mg per week.
• Stop at 2,000 mg once daily with the evening meal.
• If 2,000 mg once daily is not enough, the label suggests trying 1,000 mg twice daily before concluding the formulation has failed.

The evening meal instruction is not arbitrary. The extended-release matrix releases metformin over several hours, and evening dosing lines the peak up with overnight hepatic glucose production, which is the main target in type 2 diabetes.

Extended-release options here include Glycomet 500mg SR, Glycomet 850mg SR, Metsmall 500 SR and Metsmall 1000 SR from Dr Reddy''s.

Switching between immediate-release and extended-release

A switch is usually made for one reason: gastrointestinal intolerance. The trial data behind that decision is covered in detail in our guide to metformin side effects, and the short version is that reported diarrhoea rates in the extended-release trials were a fraction of those in the immediate-release trial.

The switch itself is straightforward. Patients on immediate-release metformin can move to extended-release once daily at the same total daily dose, up to 2,000 mg once daily. Above 2,000 mg per day, the switch does not work, because extended-release has no approved dose that high. Glycaemic control should be checked after the change rather than assumed, since the two formulations are not identical in absorption profile even at matched daily doses.

Kidney function decides eligibility before dose

The most important number in metformin prescribing is not the milligram figure, it is the estimated glomerular filtration rate. Metformin is cleared renally, and accumulation is the mechanism behind its one serious toxicity.

eGFR (mL/min/1.73 m2)	Label position
Below 30	Contraindicated
30 to 45	Starting metformin is not recommended; continuing existing treatment requires a benefit and risk assessment
Above 45	Standard dosing, with eGFR checked at least annually

eGFR should be measured before starting metformin and at least once a year afterwards, and more often in anyone at risk of declining kidney function. Age alone is a risk factor: the labelling flags age 65 and over as one of the conditions that raises the risk of metformin-associated lactic acidosis.

Contrast imaging, surgery and sick days

Metformin has to be paused around several predictable events. The label directs prescribers to stop metformin at the time of or before an iodinated contrast imaging procedure in patients with eGFR between 30 and 60, in those with a history of liver disease, alcoholism or heart failure, and in anyone receiving intra-arterial contrast. Kidney function is then rechecked 48 hours after the procedure, and metformin is restarted only if renal function is stable.

The same logic applies to surgery and to any acute illness involving dehydration, vomiting, diarrhoea or reduced fluid intake. These are the situations in which a stable dose becomes an unsafe one without the dose itself changing.

Fixed-dose combinations change the arithmetic

A large share of metformin is taken inside combination tablets, and it is easy to lose track of the total metformin dose when two products are involved. The combination itself does not raise the metformin ceiling.

Combination	Partner drug class	Example product
Metformin plus glimepiride	Sulfonylurea	Glycomet-GP 1, Glycomet-GP 2, Amaryl M 1mg
Metformin plus sitagliptin	DPP-4 inhibitor	Janumet 50mg/500mg
Metformin plus empagliflozin	SGLT2 inhibitor	Jardiance Met 5mg/500mg
Metformin plus vildagliptin	DPP-4 inhibitor	Vysov-M 50/500
Metformin plus pioglitazone	Thiazolidinedione	Pioglit MF 15

If a combination tablet is added to plain metformin, the metformin content of both has to be added together and kept inside the same daily limit. Combination products also carry the warnings of the partner drug. Anything containing glimepiride carries a real hypoglycaemia risk that plain metformin does not, which is covered in our comparison of metformin and glimepiride.

What to monitor and when

The label sets out a specific monitoring rhythm during and after titration:

• Fasting plasma glucose is the measure used during initiation and dose titration to judge response and find the minimum effective dose.
• HbA1c is measured at roughly three-month intervals once the dose is stable.
• eGFR before starting and at least annually.
• Vitamin B12 periodically, particularly with long-term use, anaemia or peripheral neuropathy.

The three-month HbA1c interval also gives the definition of failure. Primary failure is inadequate glucose lowering at the maximum recommended dose. Secondary failure is losing an adequate response after an initial period of effectiveness. Both are reasons to add a second agent rather than to push metformin past its ceiling.

Missed doses and short interruptions

Metformin has a short duration of action relative to its dosing interval, and a single missed dose is not a clinical event. The usual approach is to take the missed dose with the next meal if it is remembered soon, or to skip it entirely and resume the normal schedule. Doubling up is the one thing to avoid, because gastrointestinal tolerance is dose-dependent and a double dose reliably produces the symptoms the titration schedule was designed to prevent.

The label also notes that short-term metformin may be enough during a temporary loss of control in someone usually managed by diet alone, which is a reminder that the drug does not have to be a permanent commitment in every case.

Where dose stops being the answer

Metformin is titrated to a ceiling, and roughly at that ceiling the decision shifts from dose to drug selection. Adding a sulfonylurea, a DPP-4 inhibitor, an SGLT2 inhibitor or a GLP-1 receptor agonist each solve a different problem, with different side effect profiles and very different costs. That decision belongs with a prescriber who has the full picture, including kidney function, cardiovascular history and weight targets. Our type 2 diabetes treatment overview sets out what each of the six oral drug classes actually does.

What this guide can do is make the metformin half of that conversation precise: which dose, in which formulation, reached over how many weeks, and at what point the ceiling has genuinely been hit rather than approached and abandoned because of a titration step that moved too fast.

Medical disclaimer

This article is educational and does not replace advice from a qualified healthcare professional. Metformin requires a prescription in the United States, United Kingdom, Canada and Australia. Do not start, stop or change a diabetes medicine without speaking to your prescriber. Type 2 diabetes management involves kidney function, other medicines and individual risk factors that only a clinician who knows your history can weigh.

References

• DailyMed, Metformin Hydrochloride Tablets USP and Metformin Hydrochloride Extended-Release Tablets USP, Dosage and Administration, Contraindications and Warnings sections.
• FDA-approved prescribing information for Glucophage and Glucophage XR (metformin hydrochloride), Dosage and Administration.
• Graham GG et al. Clinical pharmacokinetics of metformin. PubMed PMID: 21241070.
• Scheen AJ. Clinical pharmacokinetics of metformin. PubMed PMID: 8743335.
• Timmins P et al. Steady-state pharmacokinetics of a novel extended-release metformin formulation. PubMed PMID: 16128603.